What is the current market size and future outlook for the vutrisiran market?
The vutrisiran market size has grown rapidly in recent years. It will grow from $0.60 billion in 2024 to $0.68 billion in 2025 at a compound annual growth rate (CAGR) of 12.8%. The growth in the historic period can be attributed to increasing awareness of hereditary transthyretin amyloidosis, rising clinical trials, increasing healthcare spending, rising patient preference for non-invasive administration methods, and rising genetic disorders.
The vutrisiran market size is expected to see rapid growth in the next few years. It will grow to $1.08 billion in 2029 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to increasing healthcare availability, rising prevalence of chronic diseases, increasing investment in research and development, growing focus on personalized medicine, and rising awareness of disease. Major trends in the forecast period include development in combination therapy, adoption of targeted therapy, advancement in personalized medicine, development in digital health technologies, and advancements in biotechnology.
Get Your Free Sample of The Global Vutrisiran Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21320&type=smp
How has the vutrisiran market evolved, and what factors have shaped its growth?
The increasing investment in research and development is expected to propel the growth of the vutrisiran market going forward. Research and development refers to innovating and improving products, services, or processes through systematic investigation and experimentation. The increasing investment in research and development (R&D)is due to government initiatives and funding, growing healthcare and pharmaceutical needs, sustainability, and environmental concerns. Research and development funding allows pharmaceutical companies to conduct clinical trials, demonstrating the drug’s long-term benefits and safety, leading to broader regulatory approvals. Additionally, RNA interference (RNAi) technology advancements improve the drug’s precision, reducing side effects and increasing patient adoption. For instance, in December 2023, according to Eurostat, a Luxembourg-based statistical office of the European Union, in 2022, the European Union’s expenditure on research and development (R&D) increased to €352 billion ($384.42 billion), marking a 6.34% rise from €331 billion ($361.48 billion) in the previous year. Therefore, the increasing investment in research and development is driving the growth of the vutrisiran
What are the major segments of the vutrisiran market?
The vutrisiran market covered in this report is segmented –
1) By Drug Class: Antisense Oligonucleotide, Nucleic Acids, Nucleotide, Nucleoside, Other Drug Classes
2) By Route Of Administration: Oral, Injectable, Subcutaneous
3) By Patient Demographics: Pediatric, Adult, Geriatric
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
Subsegments:
1) By Antisense Oligonucleotide: Single-Stranded Antisense Oligonucleotides, Double-Stranded Antisense Oligonucleotides
2) By Nucleic Acids: DNA-based Nucleic Acids, RNA-based Nucleic Acids
3) By Nucleotide: Purine Nucleotides, Pyrimidine Nucleotides
4) By Nucleoside: Purine Nucleosides, Pyrimidine Nucleosides
5) By Other Drug Classes: Peptide-Based Drugs, Protein Therapeutics
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/vutrisiran-global-market-report
Which companies dominate the vutrisiran market?
Major companies operating in the vutrisiran market are Alnylam Pharmaceuticals Inc
How will evolving trends contribute to the growth of the vutrisiran market?
The key trend in the vutrisiran market is focusing on developing innovative therapeutics, such as subcutaneous RNAi therapeutics, to provide more convenient, less frequent dosing options for the management of hereditary transthyretin-mediated (hATTR) amyloidosis. Subcutaneous RNAi therapeutics are treatments that use RNA interference technology, administered via injection under the skin, designed for sustained release. This method ensures consistent drug levels over time, improving patient convenience and adherence in treating polyneuropathy associated with hereditary transthyretin-mediated (hATTR) amyloidosis. For instance, in June 2022, Alnylam Pharmaceuticals, a US-based biopharmaceutical company, announced that vutrisiran (AMVUTTRA) was approved by the Food and Drug Administration (FDA). It is used for the treatment of polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis. It significantly improves neuropathy symptoms and halts disease progression. In the HELIOS-A Phase 3 study, over 50% of patients experienced a reversal or halt of disease manifestations. AMVUTTRA offers a promising safety profile, with no drug-related discontinuations or deaths, and a dosing regimen that may improve patient compliance.
What are the key regional dynamics of the vutrisiran market, and which region leads in market share?
North America was the largest region in the vutrisiran market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vutrisiran market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Vutrisiran Market Report 2025 Offer?
The vutrisiran market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Vutrisiran is a small interfering RNA (siRNA) therapy for hereditary transthyretin-mediated (hATTR) amyloidosis. It silences the transthyretin (TTR) gene, reducing abnormal TTR protein deposits that cause polyneuropathy and organ damage. Vutrisiran helps slow disease progression and improve neurological function, mobility, and quality of life with a longer dosing interval.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21320
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
